Last reviewed · How we verify

NCT04731584: CONVASC-I

Systemic Inflammation During Recanalization of Cerebral Arterial Occlusion

Completed Last updated 13 February 2023
What this trial tests

trial testing Blood sample in Stroke in 15 participants. Completed in 12 June 2021.

Timeline
7 April 2021
Primary endpoint
12 June 2021
12 June 2021

Quick facts

Lead sponsorHospices Civils de Lyon
StatusCompleted
Study typeOBSERVATIONAL
Enrollment15
Start date7 April 2021
Primary completion12 June 2021
Estimated completion12 June 2021
Sites4 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Hospices Civils de Lyon — full company profile →

Who can join

18 and older, any sex, with Stroke or Systemic Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Strokes management, secondary to proximal arterial occlusion, by endovascular thrombectomy (TM) is now well established. The immuno-inflammatory events of reperfusion after TM are discussed. Systemic inflammation is a major factor suggested to explain the limited recovery of the ischemic parenchyma. Understanding these phenomena is necessary before developing an immunomodulatory strategy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood sample

Trials testing the same drug.

Other recruiting trials for Stroke

Currently open trials in the same condition.

Other Hospices Civils de Lyon trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04731584.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing